Mostrar el registro sencillo del ítem

AutorMarcus, Julia L.
AutorGlidden, David V.
AutorMcMahan, Vanessa
AutorLama, Javier R.
AutorMayer, Kenneth H.
AutorLiu, Albert Y.
AutorHerrera, Orlando Montoya
AutorCasapia, Martin
AutorHoagland, Brenda Regina de Siqueira
AutorGrant, Robert M.
Fecha de acceso2015-05-15T19:22:06Z
Fecha de disponibilización2015-05-15T19:22:06Z
Fecha de publicación2014
ReferenciaMARCUS, Julia L. et al. Daily oral emtricitabine/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with men. Plos One, v.9, n.3, p.e91513, 2014.pt_BR
ISSN1932-6203
URIhttps://www.arca.fiocruz.br/handle/icict/10377
PromociónBill and Melinda Gates Foundation, Gladstone Institutespt_BR
Idiomaengpt_BR
EditorPublic Library of Sciencept_BR
Derechos de autoropen accesspt_BR
TítuloDaily oral emtricitabine/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with menpt_BR
Tipo del documentoArticlept_BR
DOI10.1371/journal.pone.0091513
Resumen en InglésIn addition to protecting against HIV acquisition, antiretroviral preexposure prophylaxis (PrEP) using topical 1% tenofovir gel reduced Herpes simplex virus type 2 (HSV-2) acquisition by 51% among women in the CAPRISA 004 study. We examined the effect of daily oral emtricitabine/tenofovir (FTC/TDF) PrEP on HSV-2 seroincidence and ulcer occurrence among men who have sex with men (MSM) in the iPrEx trial. Methods HSV-2 serum testing was performed at screening and every six months. Among HSV-2-seronegative individuals, we used Cox regression models to estimate hazard ratios (HRs) of HSV-2 seroincidence associated with randomization to FTC/TDF. We used multiple imputation and Cox regression to estimate HRs for HSV-2 seroincidence accounting for drug exposure. We assessed ulcer occurrence among participants with prevalent or incident HSV-2 infection. Results Of the 2,499 participants, 1383 (55.3%) tested HSV-2-seronegative at baseline, 892 (35.7%) tested positive, 223 (8.9%) had indeterminate tests, and one test was not done. Of the 1,347 HSV-2-seronegative participants with follow-up, 125 (9.3%) had incident HSV-2 infection (5.9 per 100 person-years). Compared with participants receiving placebo, there was no difference in HSV-2 seroincidence among participants receiving FTC/TDF (HR 1.1, 95% CI: 0.8–1.5; P = 0.64) or among participants receiving FTC/TDF with a concentration of tenofovir diphosphate >16 per million viable cells (HR 1.0, 95% CI: 0.3–3.5; P = 0.95). Among participants with HSV-2 infection, the proportion with ≥1 moderate or severe ulcer adverse event was twice as high in the placebo vs. active arm (5.9% vs. 2.9%, P = 0.02), but there were no differences in the proportions with ≥1 clinical examination during which perianal or groin ulcers were identified. Conclusions Tenofovir in daily oral FTC/TDF PrEP may reduce the occurrence of ulcers in individuals with HSV-2 infection but does not protect against HSV-2 incidence among MSM.pt_BR
AfiliaciónGladstone Institute of Virology and Immunology. San Francisco, CA, United States of America / University of California. Berkeley, CA, United States of Americapt_BR
AfiliaciónUniversity of California San Francisco. San Francisco, CA, United States of Americapt_BR
AfiliaciónGladstone Institute of Virology and Immunology. San Francisco, CA, United States of Americapt_BR
AfiliaciónAsociación Civil Impacta Salud y Educación. Lima, Perupt_BR
AfiliaciónFenway Institute. Fenway Health. Boston, MA, United States of America / Beth Israel Deaconess Medical Center. Boston, MA, United States of Americapt_BR
AfiliaciónBridge HIV. San Francisco Department of Public Health. San Francisco, CA, United States of Americapt_BR
AfiliaciónFundación Ecuatoriana Equidad. Guayaquil, Ecuadorpt_BR
AfiliaciónAsociación Civil Selva Amazónica. Iquitos, Perupt_BR
AfiliaciónFundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasipt_BR
AfiliaciónGladstone Institute of Virology and Immunology. San Francisco, CA, United States of America / University of California San Francisco. San Francisco, CA, United States of Americapt_BR
Palavras clave en InglêsHerpesvirus 2, Humanpt_BR
Palavras clave en InglêsStatistical Analysispt_BR
Palavras clave en InglêsAnti-Retroviral Agentspt_BR
Palavras clave en InglêsPre-Exposure Prophylaxispt_BR
DeCSHerpesvirus Humano 2pt_BR
DeCSAnálise Estatísticapt_BR
DeCSAntirretroviraispt_BR
DeCSProfilaxia Pré-Exposiçãopt_BR
e-ISSN1932-6203


Ficheros en el ítem

application/pdf
Nombre:
Daily oral emtricitabine tenofovir ...
Tamaño:
284.3Kb
Formato:
application/
Ver/Abrir

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem